Single-cell transcriptome analyses reveal critical roles of RNA splicing during leukemia progression

PLoS Biol. 2023 May 2;21(5):e3002088. doi: 10.1371/journal.pbio.3002088. eCollection 2023 May.

Abstract

Leukemogenesis is proposed to be a multistep process by which normal hematopoietic stem and progenitor cells are transformed into full-blown leukemic cells, the details of which are not fully understood. Here, we performed serial single-cell transcriptome analyses of preleukemic and leukemic cells (PLCs) and constructed the cellular and molecular transformation trajectory in a Myc-driven acute myeloid leukemia (AML) model in mice, which represented the transformation course in patients. We found that the Myc targets were gradually up-regulated along the trajectory. Among them were splicing factors, which showed stage-specific prognosis for AML patients. Furthermore, we dissected the detailed gene network of a tipping point for hematopoietic stem and progenitor cells (HSPCs) to generate initiating PLCs, which was characterized by dramatically increased splicing factors and unusual RNA velocity. In the late stage, PLCs acquired explosive heterogeneity through RNA alternative splicing. Among them, the Hsp90aa1hi subpopulation was conserved in both human and mouse AML and associated with poor prognosis. Exon 4 skipping of Tmem134 was identified in these cells. While the exon skipping product Tmem134β promoted the cell cycle, full-length Tmem134α delayed tumorigenesis. Our study emphasized the critical roles of RNA splicing in the full process of leukemogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Humans
  • Leukemia, Myeloid, Acute* / genetics
  • Mice
  • RNA
  • RNA Splicing / genetics
  • RNA Splicing Factors / genetics
  • Single-Cell Gene Expression Analysis*
  • Transcriptome / genetics

Substances

  • RNA
  • RNA Splicing Factors

Grants and funding

This work was supported by the National Natural Science Foundation of China (82130007 to YL, 82170171 to CC), the Sichuan Science and Technology Program (2021YFS0027 to LC, 2020YFQ0059 to CC, 2018JZ0077 to YL), the 1.3.5. Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYJC21009 to YL and ZYGD22012 to YL), the Sichuan University Postdoctoral Interdisciplinary Innovation Fund to XC, the Post-Doctor Research Project, West China Hospital, Sichuan University (2023HXBH019 to BW and 2023HXBH033 to XC), the China Postdoctoral Science Foundation (2022M722272 to JX). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.